Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.02.2016 | short review | Ausgabe 1/2016

memo - Magazine of European Medical Oncology 1/2016

Treatment of elderly and very old patients with AML

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 1/2016
Autor:
MD Elisabeth Koller

Abstract

Acute Myeloid Leukemia (AML) is a genetically heterogeneous malignant disease mainly occurring in elderly patients. The prognosis of patients over 60 years of age, which represent the majority of patients, which are diagnosed, remains poor. The main reasons for the poor outcome are the in-creasing number of comorbidities, organ impairments and nevertheless the unfavorable genetic features, pre-existing myelodysplastic changes and rising multi-drug resistance. It is also more likely that older and frail patients are not included into clinical trials and treatment decisions have to be made on general assumptions.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2016

memo - Magazine of European Medical Oncology 1/2016 Zur Ausgabe